IL1RAP and psoriasis: Two IL1RAP-targeting drugs, SPESOLIMAB and IMSIDOLIMAB, have already received regulatory approval for the treatment of inflammatory conditions such as psoriasis, ichthyosis, and Crohn’s disease.